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Abstract 
Background: Peripheral neuropathy is the most common neurological manifestation of canine hypothyroidism. 
Data concerning electrodiagnostic studies in hypothyroid associated polyneuropathy in dogs are very limited and 
usually lack a reevaluation after hormone replacement therapy. The objective of this study was to perform a detailed, 
retrospective analysis of electromyographic (EMG), motor nerve conduction velocity (MNCV), F-wave and brainstem 
auditory evoked response (BAER) findings in 24 dogs with presumptive primary hypothyroidism and polyneuropathy 
with a comparison of the results before and after initiation of levothyroxine treatment with the assessment of the 
clinical outcome.
Results: The results obtained from hypothyroid dogs showed a significant reduction in MNCV at a proximal–distal 
and middle–distal stimulation, decreased amplitudes of compound muscle action potentials (CMAP), an increased 
CMAP duration and a prolonged distal latency prior to treatment. Fifty percent of the dogs had an increased F-wave 
latency. A normal BAER recording was found in 78 % of the hypothyroid patients without vestibular impairment. Bilat-
erally increased peak V latencies and increased interpeak I–V latencies were found in the remaining individuals. Dogs 
with concurrent vestibular impairment had ipsilaterally increased peak latencies with normal interpeak latencies and 
decreased amplitudes of wave I and II. A comparison of the findings before and after 2 months of treatment revealed 
a decrease in the pathological activity on EMG, an improvement of proximal, middle and distal CMAP amplitudes and 
an increase in the proximal–distal conduction velocity in all dogs. F-wave latency improved in 38 % of dogs. The BAER 
reexamination revealed a persistent prolongation of peak I, II, III and V latencies and decreased wave I amplitude on 
the affected side in all dogs manifesting vestibular signs. Conversely, in dogs without vestibular signs, the peak V and 
interpeak I–V latencies decreased to normal values after a given time of the treatment.
Conclusions: The results indicate a demyelinating and axonal pattern of polyneuropathy in dogs with suspected 
hypothyroidism. Most of the patients without vestibular signs showed neither peripheral nor central auditory path-
way impairment, concurrent to the generalized neuropathy. The follow-up examination showed a very good clinical 
outcome and only partial improvement in electrophysiological assessment.
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Background
Canine hypothyroidism is the most common endo-
crinopathy in mature, middle- to large-sized dogs and 
is characterized by a range of clinical manifestations [1, 
2]. While the classical signs of this disease are well rec-
ognized, the correlation between hypothyroidism and 
neurologic dysfunction is less known [3]. Both central 
and peripheral neurological signs have been described 
in veterinary medicine [4]. Although the brain is con-
sidered relatively resistant to hypothyroidism in animals 
[5], seizures, disorientation, circling, coma and brainstem 
abnormalities, including central vestibular signs have 
been reported in hypothyroid dogs [3, 6, 7]. Peripheral 
nervous system syndromes, including cranial neuropa-
thies (trigeminal, facial and vestibulocochlear nerve dys-
function), laryngeal paralysis, megaesophagus and, most 
frequently, generalized neuromuscular signs, have been 
reported in canine hypothyroidism [4, 7, 8].
The pathophysiology of polyneuropathy in hypothy-
roidism is not well understood [9]. Based on human 
studies, it is hypothesized that decreased metabolism in 
neurons may lead to impaired axonal transport and, in 
consequence, axonal atrophy [10, 11]. Another explana-
tion for polyneuropathy is demyelination that is caused 
by the deposition of mucopolysaccharides in the cyto-
plasm of Schwann cells and connective tissue of the 
nerve [9, 12]. It may also be a result of vascular damage 
due to disturbances in the blood-nerve barrier [13, 14].
Polyneuropathy and myopathy associated with thyroid 
hormone deficiency in dogs may present as exercise intol-
erance, fatigue, a stiff gait, muscle atrophy, intermittent 
lameness, para- and tetraparesis [15–17]. Hypothyroid 
animals may have decreased proprioception, hypotonia 
and decreased to absent spinal reflexes [15]. According 
to previous reports, the clinical signs of peripheral nerve 
dysfunction and central vestibular disease in hypothyroid 
dogs typically resolve after 2  months of levothyroxine 
supplementation [6, 18, 19].
The electrodiagnostic findings in canine hypothyroid-
ism with neurological manifestations include increased 
insertional activity and abnormal spontaneous activity 
during electromyography (EMG), reduction in the ampli-
tudes of compound muscle action potentials (CMAP), a 
decreased motor nerve conduction velocity (MNCV) and 
brainstem auditory evoked response (BAER) abnormali-
ties [6, 8, 9]. Most of these studies were carried out on a 
very small number of dogs (case reports and case series). 
A single electrodiagnostic test without reevaluation after 
levothyroxine supplementation was performed in the 
majority of cases, particularly if complete resolution of 
the clinical signs was achieved.
The purpose of this study was a retrospective evalua-
tion of EMG, MNCV, F-wave and BAER findings in 24 
dogs with presumptive naturally occurring hypothyroid-
ism and peripheral neuropathy, and a comparison of the 
results before and after initiation of levothyroxine supple-
mentation with the assessment of the clinical outcome.
Methods
Case selection
Electrodiagnostic recordings from 34 dogs referred for 
a neurological consultation to the Department of Inter-
nal Medicine with the Clinic of Horses, Dogs and Cats, 
Wroclaw University of Environmental and Life Sciences 
between February 2010 and February 2014, were ana-
lyzed retrospectively.
Group A consisted of 24 dogs with a presumptive diag-
nosis of hypothyroidism and polyneuropathy based on 
the following criteria: (1) a hypothyroid state with a high 
probability of primary hypothyroidism based on clini-
cal findings, the hemato-biochemical blood profile and 
thyroid function test (decreased T4, fT4 and increased 
cTSH; if cTSH normal—the presence of other laboratory 
abnormalities and at least two extraneural clinical signs 
indicative of hypothyroidism), (2) neurological signs of 
progressive, generalized lower motor neuron impairment, 
(3) an electrodiagnostic evaluation, confirming peripheral 
neuropathy, (4) a positive clinical response to thyroid hor-
mone replacement therapy (THRT), (5) an unremarkable 
abdominal ultrasound, chest x-rays, cerebrospinal fluid 
examination, (6) a normal head MRI in cases with cra-
nial nerves deficits. In order to be included in the study, 
patients could not have a history of recent trauma or sur-
gery, exposure to toxins or treatment with phenobarbital.
The age of the examined animals at presentation 
ranged between 5 and 12 years (average: 9 years, median 
8.5  years) and included 9 males (1/9 neutered) and 15 
females (11/15 spayed). Subgroup A1 consisted of 11 
dogs that underwent an electrodiagnostic reexamination 
2 months after starting THRT. The detailed data regard-
ing the breeds of dogs, history and electrodiagnostic tests 
is given in Table 1.
Group B (control group) consisted of ten dogs that were 
initially admitted for a neurological examination, but were 
diagnosed with an orthopedic problem and were oth-
erwise healthy. The age of the dogs was similar to those 
from group A, and ranged between 5 and 10 years (aver-
age 8 years, mean 7 years). This group consisted of 4 males 
and 6 females (4/6 spayed). The body weight ranged from 
11 to 46  kg (mean 23  kg, median 26  kg). Hypothyroid-
ism was excluded in this group based on normal blood 
test results. MNCV recordings, CMAP latencies, ampli-
tudes and durations as well as BAER test recordings were 
documented. All the results were considered normal for 
the given age, size and limb length of the dogs based on a 
comparison with a previous report [20].
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Clinical examination
All dogs were examined clinically, orthopedically, and 
neurologically. Motor function was evaluated and motor 
deficits were classified according to the following scale: 
Grade 0—normal motor function and muscle strength, 
Grade 1—mild motor deficits, muscle weakness, ambu-
latory paresis; Grade 2–moderate deficits, non-ambu-
latory paresis and Grade 3—severe deficits, complete 
loss of strength, plegia. A basic laboratory workup for 
neuromuscular disease according to Cuddon [9], includ-
ing a hemato-biochemical blood profile and urinalysis 
was performed in all dogs. The thyroid function tests 
included measurements of total thyroxine (T4) (normal 
range 1.4–4.5 μg/dl), free thyroxine (fT4) by equilibrium 
dialysis (normal range 8–40 pmol/L), and serum canine 
thyroid stimulating hormone (cTSH) concentrations 
(normal range 0.01–0.50 ng/mL).
The electrophysiological examination was carried 
out at an ambient temperature of 22  °C with the use of 
the Nicolet Viasys Healthcare portable electrodiagnos-
tic equipment and the version 11.0 of the Viking Quest 
software. Prior to testing, dogs were premedicated with a 
combination of medetomidine at a dose of 20 μg/kg and 
butorfanol at a dose of 0.1 mg/kg administered in the tri-
ceps brachii muscle. The electrodiagnostic examination 
was performed under general anesthesia using propofol 
at an induction dose of 1–4  mg/kg and a maintenance 
dose of 0.1–0.4 mg/kg/min, respectively.
The EMG was performed in all dogs in both groups by 
intramuscular insertions of a standard concentric needle 
electrode into the appendicular and axial muscles, with 
the monopolar ground electrode placed subcutaneously 
on the animal’s flank. A semi-quantitative numerical 
scale by Kimura [21] was modified and adopted for the 
purpose of this study to evaluate the severity of EMG 
changes (Table 2).
The MNCV study and F-wave assessment were per-
formed with the use of: (1) two stimulating needle elec-
trodes, (2) a concentric recording needle electrode, 
placed in the plantar interosseous muscle and (3) a 
ground electrode, placed between the stimulating and 
recording electrodes. The MNCV measurements were 
obtained in dogs in both groups in the sciatic/tibial 
nerves using a single supramaximal electrical stimulus 
with a 0.1  ms (ms) duration at three stimulation points 
according to Walker et al. [22]: proximal—caudal to the 
greater trochanter of the femur; middle—at the level of 
stifle and caudal to the distal end of the femur; and dis-
tal—above the hock, lateral to the gastrocnemius tendon 
of the tuber calcanei. The recordings of the MNCV and 
CMAP latency, duration and amplitude were analyzed 
and compared between groups A and B. The same vari-
ables were analyzed in group A1, before and 2  months 
after initiating THRT. The F-wave evaluation was based 
on the measurement of the latency of the recorded 
F-waves in comparison to the expected minimum F-wave 
latency calculated according to the following formula 
3.45 + 0.33× limb length (cm) for the sciatic/tibial nerve [20]. 
The limb length was measured on an extended limb from 
the level of the greater trochanter of the femur to the 
distal tip of the 3rd digit. Responses were elicited by 16 
stimuli and the smallest latency period before the F-wave 
complex was measured.
The BAER test was performed in both groups of dogs 
using a previously described technique [20]. Briefly, 
standard subcutaneous needle-electrodes were placed in 
the mastoid reference (M), where the recording electrode 
was positioned at the vertex, the reference electrode 
was placed at the base of the ear and the ground elec-
trode was placed at the midline of the 1st cervical ver-
tebra. The auditory stimulus (1000 sweeps) was emitted 
through tubal insert ear phones at a 90 dB nHL intensity 
to the tested ear. A masking noise of 60  dB was simul-
taneously applied to the contralateral ear. All recordings 
were performed in rarefaction polarity, with a frequency 
setting of 11  Hz. The analysis of the BAER recording, 
obtained from the both ears in each individual, included 
an identification of waves I–V, measurement of their 
amplitudes and latencies and the determination of the 
I–V interpeak latency (IPL). All those variables were 
compared between the dogs in group A and B. In case 
of abnormal BAER recordings at the first examination, 
the comparison of the results before and after the initia-
tion of the therapy was additionally performed in each 
individual. The BAER examination was preceded by an 
otoscopic examination.
The follow-up examination, which included a reevalu-
ation of the clinical and neurological status as well 
as carrying out thyroid function tests was performed 
approximately 1  month after starting THRT at a dose 
of 20  µg/kg twice daily (BID) in all dogs in group A. 
The dosage was further adjusted according to the clini-
cal response, the results of laboratory tests and clinical 
Table 2 Modified semi-quantitative numerical scale 
for  the electromyographic evaluation of  the degree 
of pathological potentials
Grade Description
0 No pathological potentials
1 Very rare denervation potentials
2 Sporadic pathological activity recorded in two or 
more places
3 Frequent pathological activity recorded regardless of 
the position of the needle electrode
4 Abundant pathological activity recorded regardless 
of the position of the needle electrode
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findings. Electrodiagnostic reevaluation was performed 
2 months after initiating the THRT and was always con-
ducted by this same examiner for the respective cases. 
Detailed information on the individual cases is presented 
in Table 1.
The results of the electrodiagnostic measurements 
were subjected to statistical analysis, using Excel 6.0 soft-
ware and StatSoft Inc Statistica 10 software. The non-
parametric Mann–Whitney U test was used to compare 
non-parametric values in the hypothyroid and control 
group. Student’s t test was used to compare parametric 
data before and after starting levothyroxine treatment. 
P < 0.05 was considered significant.
Results
Clinical and electrodiagnosting findings prior 
to levothyroxine supplementation
All of the 24 dogs in group A (hypothyroid) were pre-
sented with generalized weakness and hyporeflexia. 
Lethargy was noted in 16/24, excess weight in 14/24, 
bradycardia in 8/24 and typical dermatological signs in 
5/24. Motor deficits were evaluated as Grade “1” in 8/24 
dogs, Grade “2” in 11/24 individuals and Grade “3” in 
5/24 canine patients (Table 1). Five hypothyroid patients 
additionally manifested signs of peripheral vestibular 
dysfunction (head tilt, horizontal nystagmus, vestibular 
strabismus). The duration of clinical signs varied from 
1 to 12  weeks (median 6  weeks, mean 5  weeks) with a 
slow progression of generalized weakness in all dogs. 
According to the owners’ reports, the motor deficits were 
acutely exacerbated in seven individuals prior to the con-
sultation. The onset of vestibular signs was also acute in 
all cases.
The diagnosis of hypothyroidism in group A was based 
on laboratory findings including decreased tT4 (24/24), 
decreased fT4 (22/24) and increased cTSH in 15/24. All 
dogs with normal cTSH (9/24) had moderate to severe 
fasting hypercholesterolemia, 7/9 dogs had fasting hyper-
triglyceridemia, 4/9 were presented with normocytic 
anemia, 2/9 had mildly increased aspartate aminotrans-
ferase and creatinine kinase activity. In total, 22/24 dogs 
in group A had hypercholesterolemia, 18/24 had hyper-
triglyceridemia, 7/24 had anemia and 6/24 dogs had a 
mildly increased aspartate aminotransferase and creati-
nine kinase activity.
The EMG examination in group A revealed increased 
insertional activity in 14/24 dogs, multifocal patterns of 
fibrillation potentials (FPs) in all 24 patients and positive 
sharp waves in 18/24 dogs. The changes were notice-
able in all four limbs in all dogs in group A. The abnor-
mal activity was equally appreciated in the proximal 
and distal parts of the front and hind limbs. Additional 
FPs were present in the axial muscles of eight dogs. The 
severity of individual EMG changes for each individual 
is shown in Table  1. The MNCV study in the hypothy-
roid group revealed a statistically significant reduction 
in the conduction velocity at the proximal–distal (26–
54 m/s) and middle-distal stimulation (20–48 m/s) when 
compared to the control group (Table  3). The detailed 
analysis of CMAP parameters revealed a prolonged 
distal latency, decreased CMAP amplitudes and an 
increase in the CMAP duration at all stimulation points 
in group A (Table  3). The F-wave was recorded in 16 
dogs from group A (Cases No. 1–11, 13, 15, 16, 21, 22). 
The F-wave latency was increased by more than 2 ms in 
eight patients (50 %) when compared to the expected F 
wave latency calculated for each dog (cases 1–6, 10, 11) 
(Table 1).
The BAER examination was performed in 14 patients 
in group A, including five dogs with vestibular signs. 
Table 3 Comparison of  motor nerve conduction variables in  hypothyroid dogs and  healthy controls before  and 
after treatment
Statistically significant differences are indicated in italics. THRT thyroid hormone replacement therapy
Group parameter Group A (hypothyroid) 
[n = 24]
Group B (control) 
[n = 10]
P value Group A1 before THRT 
[n = 11]
Group A1 after THRT 
[n = 11]
P value
MNCV prox-dist [m/s] 44.2 ± 7.6 65.4 ± 2.5 <0.05 38.2 ± 6.9 45.7 ± 6.2 <0.05
MNCV mid-dist [m/s] 40.1 ± 7.3 60.8 ± 2.2 <0.05 34.5 ± 7.1 36.2 ± 6.3 0.57
Latency prox [ms] 9.2 ± 1.7 7.8 ± 0.4 0.31 – – –
Latency mid [ms] 7.1 ± 1.6 5.8 ± 0.3 0.25 – – –
Latency dist [ms] 6.1 ± 1.1 3.0 ± 0.4 <0.05 5.6 ± 1.1 5.5 ± 1.2 0.89
Amplitude prox [mV] 5.7 ± 2.3 10.2 ± 1.2 <0.05 4.5 ± 1.1 7.6 ± 1.3 <0.05
Amplitude mid [mV] 6.3 ± 2.3 12.4 ± 2.3 <0.05 5.6 ± 1.6 8.8 ± 1.6 <0.05
Amplitude dist [mV] 7.7 ± 1.5 14.1 ± 2.5 <0.05 7.4 ± 1.2 11.0 ± 1.4 <0.05
Duration prox [ms] 9.2 ± 2.7 4.7 ± 0.5 <0.05 11.2 ± 2.6 9.9 ± 2.1 0.2
Duration mid [ms] 9.1 ± 2.1 4.9 ± 0.6 <0.05 10.7 ± 2.0 9.7 ± 1.6 0.19
Duration dist [ms] 8.7 ± 2.5 4.2 ± 0.7 <0.05 9.9 ± 2.0 9.3 ± 1.9 0.45
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Dogs No. 2, 4, 14, 16 and 18, manifesting vestibular dys-
function, had increased peak I, II, III and V latencies with 
a normal I–V IPL and decreased amplitudes of wave I 
and II on the affected side when compared to group B 
(Table 4). The BAER recordings in 7/9 hypothyroid dogs 
without clinical vestibular dysfunction did not differ sig-
nificantly from the control group regarding the analyzed 
parameters. The remaining two dogs (No. 7 and 13) 
had bilaterally increased peak V latencies and increased 
I–V IPL latencies. Dog No. 7 had unilaterally decreased 
amplitudes in the entire waveform (Table 4).
The results of the clinical, neurological and laboratory 
investigations in group B (control group) were within nor-
mal limits. The EMG examination of the control limbs 
showed electrically silent muscles with normal inser-
tional activity. MNCV at the proximal–distal stimulation 
ranged from 62 to 71 m/s and from 57 to 64 m/s at the 
middle-distal stimulation site. The comparison of nerve 
conduction studies in dogs from group A and B is shown 
on Fig. 1. F wave latency values did not exceed expected 
latency values by more than 2 ms. The results of the BAER 
are presented in Table 4.
Table 4 Comparison of the BAER results between the control group and hypothyroid dogs with and without vestibular 
signs before and after initiating treatment with levothyroxine
Significant differences are indicated in italics. a excluding cases No. 7 and 13. BT before treatment, AT after treatment [2 months], L left ear, R right ear
Latency [ms] Interpeak latency Amplitude [µV]
I II III V I–V I II III V
Group B (n = 10)
 Range 1.9–2.22 2.72–3.06 3.38–3.76 4.32–4.79 2.42–2.57 2.5–3.2 1.8–2.3 0.8–1.2 1.6–2.1
 Mean 2.1 2.93 3.55 4.61 2.52 2.9 2.1 1.1 1.9
Group A not vestibulara (n = 7)
 Range 2.0–2.26 2.88–3.07 3.35–3.74 4.4–4.8 2.4–2.6 2.6–3.1 1.7–2.4 0.6–1.1 1.5–1.9
 Mean 2.15 2.99 3.48 4.68 2.54 2.9 2.1 0.8 1.8
Group A vestibular (n = 5) BT
 Ipsilateral
  Range 2.45–2.58 3.15–3.27 3.84–4.0 4.99–5.3 2.54–2.68 0.9–1.8 1.1–1.5 0.6–0.9 1.4–1.8
  Mean 2.47 3.18 3.91 5.13 2.59 1.5 1.3 0.7 1.7
 Contralateral
  Range 2.2–2.3 2.85–3.05 3.44–3.8 4.48–4.82 2.3–2.62 2.3–2.9 1.7–2.2 0.6–1.0 1.5–2.0
  Mean 2.24 2.94 3.63 4.72 2.53 2.7 2.0 0.8 1.8
Group A vestibular (n = 5) AT
 Ipsilateral
  Range 2.36–2.58 3.15–3.23 3.85–3.9 4.9–5.13 2.5–257 1.4–2.2 1.5–2.0 0.7–10 1.4–1.9
  Mean 2.51 3.18 3.89 5.09 2.55 1.8 1.7 0.8 1.7
 Contralateral
  Range 2.2–2.44 2.84–3.05 3.41–3.83 4.46–4.9 2.23–2.52 2.4–2.8 1.7–2.1 0.6–1.0 1.5–2.1
  Mean 2.29 2.92 3.66 4.75 2.45 2.6 1.9 0.8 1.8
Dog No. 7 BT
 L 2.22 2.92 3.81 5.14 2.92 2.3 1.7 0.7 1.7
 R 2.21 3.03 3.83 5.25 3.04 1.5 1.1 0.3 1.1
Dog No. 7 AT
 L 2.2 2.91 3.77 4.81 2.61 2.4 1.7 0.8 1.7
 R 2.21 3.04 3.8 4.83 2.62 1.7 1.4 0.6 1.5
Dog No. 13 BT
 L 2.05 3.09 3,76 5.28 3.23 2.5 2.1 1.1 2.0
 R 2.08 3.1 3.79 5.35 3.27 2.4 2.2 1.0 1.8
Dog No. 13 AT
 L 2.04 2.81 3.7 4.59 2.54 2.5 2.3 1.1 1.7
 R 2.05 2.89 3.75 4.62 2.58 2.5 2.0 0.9 1.9
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Clinical and electrodiagnosting findings after initiation 
of levothyroxine supplementation
In group A, the first follow-up clinicopathological exami-
nation was performed 1  month after starting the levo-
thyroxine treatment. At that time, all the studied dogs 
were more alert and active. The neurological evaluation 
revealed improvement in motor function by at least one 
Grade in 19/24 dogs. Dogs that showed no improvement 
after 1  month of the therapy and had a decreased tT4 
level (No. 4 and No. 8) were administered a double levo-
thyroxine dose (40 µg/kg BID). Dogs No 1, 5 and 9 had 
a tT4 level at a normal–low range. Because those dogs 
did not show a noticeable neurological improvement, 
levothyroxine supplementation was increased to 30  µg/
kg BID. Dog No. 19 had a mildly increased serum tT4 
concentration. Therefore, the levothyroxine dosage was 
decreased to 15 µg/kg BID.
Two months after initiating THRT, the results of the 
follow-up thyroid function tests and clinical examination 
were within normal limits in all 24 dogs. All overweight 
dogs lost weight. However, eight of them still exceeded 
recommended body mass. The majority of the vestibular 
signs resolved. Three dogs had a mild, persistent head tilt 
(No. 2, 16, 18). A full recovery of the motor function (Grade 
“0") was achieved in 13/24 dogs (No. 12–24). Eleven dogs 
that were initially scored as Grade “3" in 5 cases and Grade 
“2" in 6 cases (No. 1–11 in Table  1) showed an improve-
ment to Grade “1" (ambulatory tetraparesis). This group 
was subjected to electrodiagnostic reexamination and 
named A1.
The EMG examination showed decreased pathological 
activity in all dogs. This improvement was from Grade 
“4" to “3" in 2/11 dogs, from Grade “4" to “2" in 2/11 dogs, 
from Grade “3" to “2" in 4/11 individuals and from Grade 
“3” to “1” in 3/11 dogs, as shown in Table 1. The analysis 
of the MNCV recordings showed statistically significant 
improvement of the proximal, middle and distal CMAP 
amplitudes and the proximal–distal conduction velocity 
when compared to the results before treatment (Table 3). 
The middle–distal conduction velocity, CMAP latencies 
and durations did not differ significantly before and after 
starting treatment in group A1 (Table  3). The F-wave 
Fig. 1 The comparison of nerve conduction studies in dogs from group A and B. The recording on the left was obtained from an 8-year-old mixed-
breed dog from group B. The MNCV was 61–64 m/s and it was considered normal. The recording on the right was obtained from a 7-year-old 
Golden Retriever with suspected primary hypothyroidism. The MNCV was decreased to 30–31 m/s. Decreased CMAP amplitudes and increased 
CMAP duration (temporal dispersion) at all stimulation points were observed (distal A1, middle A2, proximal A3)
Page 8 of 10Giza et al. Acta Vet Scand  (2016) 58:32 
was reexamined in the eight dogs that had a prolonged 
F-wave latency at the first examination (No. 1–6 and 10, 
11). After a 2 month THRT therapy, there was no signifi-
cant improvement in the F-wave latency in 5/8 dogs. The 
F-wave latency reached the normal value in 2/8 dogs. In 
one individual (dog No. 6), the latency shortened mark-
edly, but the value still exceeded the expected F-wave 
latency by >2 ms (Table 1).
The BAER examination was repeated in five individuals 
with vestibular signs (dogs No. 2, 4, 14, 16 18) and two 
other dogs with an abnormal BAER recording during the 
first examination (No. 7 and 13) after 2 months of THRT. 
The second test revealed persistent prolongation of peak 
I, II, III and V latencies and a decreased wave I amplitude 
on the affected side in all dogs manifesting vestibular 
signs. The amplitude of wave II increased significantly in 
this group after replacement therapy (Table  4). In dogs 
without vestibular signs (No. 7 and 13), the peak V laten-
cies and I–V IPL reached normal values after initiating 
therapy. Amplitudes in Dog No. 7 that were decreased 
prior to therapy increased markedly when measured at 
the second time point. However, they were lower than 
those obtained from the contralateral ear (Table 4).
Discussion
Diagnosis of polyneuropathy in hypothyroidism
Insufficient secretion of thyroid hormones is consid-
ered as a possible cause of polyneuropathy in 2–4  % of 
human patients [23]. Neurological abnormalities have 
been described in 6–29  % of dogs with naturally occur-
ring hypothyroidism [1]. Peripheral neuropathy is the best 
documented neurologic manifestation of this disease in 
canine patients [8, 18]. However, a definitive diagnosis of 
canine primary hypothyroidism is complex [2]. The serum 
cTSH concentration has a high specificity for the diagno-
sis of hypothyroidism in dogs (more than 90 %) when the 
baseline serum T4 or fT4 concentration is concurrently 
low [24]. However, 20–40 % of dogs with primary hypo-
thyroidism have normal cTSH levels, which gives the test 
low sensitivity [2]. A similar percentage of dogs with nor-
mal cTSH levels and decreased T4 and fT4 was present in 
our study (37.5 %). Caution should be taken in diagnos-
ing hypothyroid neuropathy based only on a concurrent 
presence of low thyroid hormone levels [9]. Therefore, the 
presence of typical, extraneural clinical signs and accom-
panying hypercholesterolemia was required in this study 
to strengthen the suspicion of primary hypothyroidism 
in cases with normal cTSH. Despite the fact that a large 
number of additional tests was performed in order to 
rule out most systemic diseases, the nonthyroidal illness 
syndrome cannot be entirely excluded. Furthermore, we 
cannot exclude the possibility that symptoms in some 
dogs with acquired polyneuropathies of non-thyroidal 
etiology may resolve over a 2-month period. Hence, 
chronic inflammatory demyelinating polyneuropathy and 
distal denervating disease [9] may have been unintention-
ally included in the study.
The results indicate both a demyelinating and axonal 
pattern of polyneuropathy in dogs with a thyroid hor-
mone deficiency. It is usually difficult to unequivocally 
distinguish between primary axonal and primary demy-
elinating polyneuropathy (i.e., neuropathy with exten-
sive demyelination is often accompanied by slight axonal 
degeneration) [21]. Hypothyroid human patients have 
features of both axono and myelinopathy with a predomi-
nance (52–57 %) of demyelinating abnormalities in nerve 
conduction studies [11, 23, 25]. A prolonged CMAP 
and F-wave latency, a decrease in the nerve conduction 
velocity and temporal dispersion indicate demyelinating 
changes in our patients. Decreased CMAP amplitudes 
and EMG findings, which were also found in our study, 
stand for axonal involvement [26]. However, they may 
also indicate myopathy, especially in cases with elevated 
aspartate aminotransferase and creatine kinase activity 
[27]. In a study performed by Rossmeisl [27], a subclini-
cal myopathy was the only electrodiagnostic finding in 
chronically hypothyroid dogs. No evidence of polyneu-
ropathy, either clinical, or electrodiagnostic, was found in 
nine dogs with experimentally induced hypothyroidism. 
It has been suggested that immunological dysregulation 
contributes to peripheral nerve impairment in naturally-
occurring hypothyroidism [27].
Electrodiagnostic exam during the course of levothyroxine 
treatment
After initiation of levothyroxine supplementation, a range 
of electrophysiological findings have been described in 
human patients. According to Kececi et al. [25], polyneu-
ropathy in hypothyroid patients can be reversed within 
3  months using THRT. Significant improvement in 
MNCV, motor distal latency and amplitude values were 
reported. Nemni et al. [28] described complete recovery 
in the clinical status and a significant improvement in 
motor and sensory NCV, distal latency and amplitude in 
two patients following a 3 months replacement therapy. 
A similar improvement was observed after 6  months of 
supplementation in the remaining two patients. On the 
other hand, other authors demonstrated that nerve con-
duction studies did not show significant improvement, 
even after long-term replacement therapy [11, 23]. The 
reports regarding electrodiagnostic studies after replace-
ment therapy in veterinary medicine are very limited. 
Budsberg et al. [15] noted a complete resolution of patho-
logical EMG activity in three out of four dogs and par-
tial improvement in the remaining dog after 2 months of 
levothyroxine supplementation. Similarly, Jaggy et al. [8] 
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reported a complete improvement of EMG activity and 
MNCV variables in one hypothyroid dog with LMN signs 
2 months after initiating replacement therapy. Our study 
showed that regardless of the clinical outcome, only some 
electrodiagnostic variables (CMAP amplitudes, proxi-
mal–distal MNCV and EMG) improved significantly 
after 2 months of replacement therapy in group A1.
Hypothyroidism and BAER
Thyroid hormone deficiency has also been associated with 
auditory and vestibular system dysfunction in human [29] 
and canine patients [6, 8]. Vestibular signs may be the only 
clinical manifestation of concurrent, underlying poly-
neuropathy [8]. Vestibulocochlear nerve impairment can 
be associated with or occur independently of peripheral 
neuropathy [9]. All dogs in our study were presented with 
generalized polyneuropathy and 21 % of them manifested 
peripheral vestibular signs before treatment. The BAER 
findings, including ipsilaterally delayed peak latencies with 
a normal interpeak latency and markedly decreased wave 
I amplitude, which did not improve after treatment, are 
suggestive of vestibulocochlear neuropathy. The unilateral, 
isolated cranial nerve deficit may possibly be associated 
with a myxedematous compression of the nerve (in this 
case vestibulocochlear) as it exits through the foramen of 
the cranium [9]. The BAER examination in hypothyroid 
dogs without vestibular manifestation was within nor-
mal limits in 78 % of cases. The remaining individuals had 
bilaterally prolonged peak V latency and the I–V interpeak 
latency, indicating central conduction dysfunction. Jaggy 
et  al. [8] reported that two hypothyroid dogs presenting 
with generalized LMN dysfunction had concurrent BAER 
abnormalities (bilaterally prolonged latencies or lack of 
response) without presenting vestibular signs. Thorn-
ton and Jarvis [29] reported a significant reduction in the 
amplitudes of waves III and V and an increase in the I–V 
interpeak latency (iPL) in the BAER in hypothyroid human 
patients. They stated that those abnormalities may be 
explained by the low body temperature of those individu-
als rather than retrocochlear involvement. In our study, the 
body temperature of the patients was within normal limits. 
Hence, we cannot concur with this explanation. However, 
the thyroid hormone is known to control protein synthe-
sis and myelin production in the central auditory pathway 
[30]. In addition, T4 also acts as a neurotransmitter in the 
central nervous system [30]. This may be an explanation 
for central conduction dysfunction that was detected using 
the BAER in our patients. It has been suggested that BAER 
abnormalities and coexistent polyneuropathy in the course 
of acquired hypothyroidism may also be explained by seg-
mental demyelination [6].
A two-month levothyroxine treatment resulted in a sig-
nificant clinical improvement of the peripheral vestibular 
signs in our patients. A very good clinical outcome in 
dogs with vestibular disease and hypothyroidism was 
also reported by others [6, 8]. However, a mild, persistent 
head tilt was observed within 2 months of THRT in 77 % 
of the canine patients reported by Jaggy et  al. [8] and 
60 % of the dogs in our study.
Based on the BAER reexamination, we found that 
only partial improvement was achieved 2  months after 
the treatment initiation. In other veterinary reports, 
the complete resolution of BAER abnormalities was 
achieved after 6 weeks of treatment in one dog [6], and 
3–5 months in two dogs [8].
Conclusions
The results of the electrodiagnostic assessment in dogs 
with presumptive hypothyroidism and polyneuropathy 
showed features of both demyelination and axonal dam-
age in the peripheral nerves. Most of the patients without 
vestibular signs showed neither peripheral nor central 
auditory pathway impairment, concurrent to the gener-
alized neuropathy. The follow-up examination showed a 
very good clinical outcome and only partial improvement 
of the electrophysiological test results.
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